VRNS CFO Sells 51,889 Shares Worth $2.9M in 10b5-1 Trade
Varonis Systems (VRNS) Form 4 – Insider Transaction Chief Financial & Operating Officer Guy Melamed sold 51,889 common shares on 08/01/2025 under a pre-arranged Rule 10b5-1 plan.
Rhea-AI Filing Summary
Varonis Systems (VRNS) Form 4 – Insider Transaction
Chief Financial & Operating Officer Guy Melamed sold 51,889 common shares on 08/01/2025 under a pre-arranged Rule 10b5-1 plan. The shares were disposed at a weighted-average price of $55.10 (range $55.01–$55.24), generating proceeds of roughly $2.9 million. Following the sale, Melamed’s direct ownership stands at 470,602 shares.
No derivative securities were involved and no acquisitions were reported. The filing signals a reduction of approximately 10% of Melamed’s prior direct stake, yet he retains a sizeable position. Because the transaction was executed through a 10b5-1 program, it was scheduled in advance and may not reflect current views on VRNS valuation.
Positive
- None.
Negative
- CFO & COO Guy Melamed sold 51,889 VRNS shares (~$2.9 m), reducing his direct stake to 470,602 shares.
Insights
TL;DR: Planned sale of 51.9k shares by VRNS CFO is modestly negative but not alarming.
The $2.9 m sale trims Melamed’s holding to 470.6k shares, about a tenth reduction by share count. Insider selling by senior officers often raises concern, yet the use of a 10b5-1 plan limits informational value; timing and price were likely predetermined. Volume is small relative to VRNS’s ~110 m shares outstanding, so supply impact is negligible. I view the filing as neutral to slightly negative for sentiment, with no direct operational or financial implications.
TL;DR: Governance risk low; sale complies with 10b5-1 and disclosed details.
The company demonstrates sound compliance by disclosing weighted average pricing and offering to furnish granular trade data on request. Execution under Rule 10b5-1 reduces litigation and perception risk. No red flags such as clustered insider selling or option exercises appear. Therefore, from a governance standpoint, the event is largely non-impactful.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, par value $0.001 per share | 51,889 | $55.10 | $2.86M |
Footnotes (2)
- F1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.01 to $55.24, inclusive. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer, or a shareholder of the Issuer full information regarding the number of shares sold at each separate price.
FAQ
What was the average sale price reported in the Form 4?
Was the VRNS insider sale executed under a 10b5-1 plan?
Did the Form 4 disclose any derivative security activity?
Is this insider sale considered material to Varonis Systems investors?
AI-generated analysis. How Rhea-AI works. Not financial advice.